CAR-T细胞过继免疫治疗后神经毒性的临床表现、管理与生物标志物
该研究在麻省总医院描述了25例接受CAR-T细胞治疗后出现神经毒性综合征的成人患者的临床表现与管理,其中48%为1-2级神经毒性,52%为3-4级。CAR-T输注时血小板计数较低与更严重神经毒性相关(P=0.030),铁蛋白峰值与神经毒性分级较高相关,3-4级神经毒性负向影响总生存(P=0.013)。
要点
- 25例CAR-T治疗后神经毒性患者中,48%为1-2级,52%为3-4级。
- CAR-T输注时血小板计数较低与更严重神经毒性相关(P=0.030)。
- 3-4级神经毒性负向影响总生存(P=0.013),中位OS为54.7周。
核心结论
- CAR-T细胞治疗后神经毒性常见且可能危及生命,其管理需在前瞻性临床试验中评估。
研究设计与样本
- 在麻省总医院描述25例接受CAR-T细胞治疗后出现神经毒性综合征的成人患者的临床表现与管理。
- 队列包括24例接受CD19靶向CAR-T细胞治疗的患者(非霍奇金淋巴瘤23例,急性淋巴细胞白血病1例)和1例接受α-甲胎蛋白靶向CAR-T细胞治疗的肝细胞癌患者。
主要发现
- 25例患者中12例(48%)发生1-2级神经毒性,13例(52%)为3-4级神经毒性。
- CAR-T细胞输注时血小板计数较低与更严重神经毒性相关(P=0.030)。
- 细胞因子释放综合征发生于25例中的24例(96%)。
- 血清铁蛋白水平在神经系统症状出现时达峰值,较高铁蛋白水平与较高神经毒性分级相关。
- 3-4级神经毒性与总生存(OS)负相关(P=0.013),整个队列中位OS为54.7周。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor (CAR) T cells have emerged as a promising class of cell-based immunotherapy in refractory malignancies. Neurotoxicity represents a common and potentially life-threatening adverse effect of CAR T cells, and clinical experience is limited. Here, we describe the clinical presentation and management of 25 adult patients who presented with neurotoxic syndromes after CAR T-cell therapy at the Massachusetts General Hospital. This cohort includes 24 patients treated with CD19-directed CAR T cells for non-Hodgkin lymphoma (n = 23) and acute lymphoblastic leukemia (n = 1), and 1 patient treated with α-fetoprotein-directed CAR T cells for hepatocellular carcinoma (n = 1). Twelve of the 25 patients (48%) developed grade 1-2 neurotoxicity and 13 patients (52%) presented with grade 3-4 neurotoxicity. We found that lower platelet counts at time of CAR T-cell infusion were associated with more severe neurotoxicity (P = .030). Cytokine release syndrome occurred in 24 of 25 patients (96%). Serum levels of ferritin peaked with onset of neurologic symptoms, and higher ferritin levels were associated with higher neurotoxicity grade. Grade 3-4 neurotoxicity correlated negatively with overall survival (OS) (P = .013). Median OS of the entire cohort was 54.7 weeks. Eight patients (32%) with grade 3-4 neurotoxicity were deceased at database closure, whereas none died with neurotoxicity grade 1-2. High pretreatment lactate dehydrogenase was frequently encountered in lymphoma patients with grade 3-4 neurotoxicity and correlated negatively with progression-free survival (P = .048). We did not find evidence that steroid use ≥7 days altered the patient's outcome when compared with <7 days of steroids. Management of CAR T cell-mediated neurotoxicity warrants evaluation in prospective clinical trials.
引用
- Karschnia P, Jordan JT, Forst DA, et al. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood. 2019. PMID: 30808634. doi:10.1182/blood-2018-12-893396
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。